tony w
Current Pain and Headache Reports
The Journal of Laryngology & Otology
Arthritis Care & Research
Current Pain and Headache Reports
Current Pain and Headache Reports
The American Journal of Emergency Medicine
In principle, the law that constrains the marketing of nutrient supplements in the U.S. is “DSHEA,” or, the Dietary Supplement Health And Education Act (of 1994). In practice, the law of unintended consequences may exert an even greater influence.I write this in the immediate aftermath of a meeting with an innovative nutrient supplement company…
Can a company say to its employees, “We have to weigh you because our shareholders want to know how overweight you are,” or “Let me take your blood pressure; our institutional investors need to know.” A working group whose members include Humana, IBM, Johnson & Johnson, Merck, PepsiCo, Unilever, and South African insurer Discovery Ltd. Companies…
By Kathryn Doyle (Reuters Health) – – Teens with celiac disease, or any chronic disease, face extra hurdles transitioning into the adult healthcare system, but there are very few guidelines for how to make this transition smoother, according to a European consensus report. Teens with celiac disease, an immune disorder in which people cannot tolerate the gluten protein found in wheat, rye and barley, should gradually assume exclusive responsibility for their own care, learning how to follow a gluten-free diet and the consequences of not following it, the authors write. “Adolescence is a period of time where young people like to revolt and change things and they may be tempted to leave their gluten free diet, which puts certain restraints on their life,” said senior author Dr. Steffen Husby of Hans Christian Andersen Children’s Hospital, Odense University Hospital in Denmark.
By Ben Hirschler and Leigh Thomas LONDON/PARIS (Reuters) – French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover fight after the U.S. cancer firm rebuffed its approaches. The decision to target Medivation marks a return to the biotech takeover trail for Sanofi, which is looking to new cancer treatments to bolster its portfolio and help offset declining sales of mainstay diabetes drug Lantus. Sanofi’s non-binding proposal is to buy Medivation for $52.50 per share in cash, representing a 50 percent premium over the San Francisco-based firm’s two-month volume-weighted average share price prior to takeover rumors.